Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial - 21/08/11
Doi : 10.1016/j.jaad.2004.12.011
Niels K. Veien, MD, PhD a, ⁎ 
, Michael Busch-Sørensen, MD b, Birgitte Stausbøl-Grøn, MD c
, Michael Busch-Sørensen, MD b, Birgitte Stausbøl-Grøn, MD c a From the Dermatology Clinic
b Merck Research Laboratories
c Department of Dermatology, Århus University Hospital
Correspondence to: Niels K. Veien, The Dermatology Clinic, Vesterbro 99, DK-9000 Aalborg, Denmark.Aalborg, Glostrup, and Århus, Denmark
Abstract |
In a randomized, double-blind, placebo-controlled 4-week trial, 59 patients with moderate to severe atopic dermatitis were treated orally with 10 mg of the leukotriene antagonist montelukast. Forty-seven patients completed the study. No difference in efficacy was seen among patients who received montelukast and the group given a placebo.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by Merck, Sharp & Dohme. Disclosure: The authors Niels K. Veien and Birgitte Stausbøl-Grøn have no financial interest in Merck, Sharp & Dohme and are not paid consultants for the company. Reprints not available from the authors. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 53 - N° 1
P. 147-149 - juillet 2005 Retour au numéro
Article précédent
- June iotaderma (#137)
- Jeffrey D. Bernhard
- Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: An open pilot study
- Simin Ada, Deniz Seçkin, İrem Budakoğlu, Fatma Nurhan Özdemir
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?